文献速递贫血与红细胞疾病血栓与止血

肿瘤患者微血管病性溶血性贫血的诊疗

How I treat microangiopathic hemolytic anemia in patients with cancer.
PubMed 文献 · Blood · 2021-01-01

本文综述肿瘤患者出现微血管病性溶血性贫血(MAHA)伴血小板减少时提示血栓性微血管病(TMA),需鉴别肿瘤本身、治疗相关或偶发TTP/aHUS等病因,并据此制定治疗策略,强调治疗基础肿瘤和停用可疑药物。

要点

  • 肿瘤患者MAHA伴血小板减少需考虑TMA,鉴别病因是治疗关键。
  • 肿瘤直接相关MAHA/DIC以治疗基础恶性肿瘤为主,血浆置换常无效。
  • 药物性TMA应停用可疑药物,偶发TTP/aHUS需及时针对性治疗。

核心结论

  • 肿瘤患者MAHA伴血小板减少提示TMA,需区分肿瘤相关、治疗相关或偶发TTP/aHUS以指导治疗。
  • 治疗基础恶性肿瘤对控制肿瘤相关TMA或DIC至关重要,药物性TMA应停用可疑药物。

主要发现

  • 肿瘤患者TMA可能直接与恶性肿瘤相关(初诊或疾病进展)、与治疗相关或为偶发诊断。
  • 广泛微血管转移或骨髓广泛受累可导致MAHA和血小板减少,脓毒症或肿瘤本身可诱发DIC。
  • 肿瘤治疗可导致TMA,包括剂量依赖性毒性或药物依赖性抗体介导的免疫反应。

临床怎么用

  • 对肿瘤患者出现MAHA伴血小板减少应评估TMA,鉴别偶发TTP/aHUS、DIC和药物性TMA。
  • 肿瘤相关TMA或DIC应尽可能治疗基础恶性肿瘤,药物性TMA应停用可疑药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Microangiopathic hemolytic anemia (MAHA) with thrombocytopenia, suggests a thrombotic microangiopathy (TMA), linked with thrombus formation affecting small or larger vessels. In cancer patients, it may be directly related to the underlying malignancy (initial presentation or progressive disease), to its treatment, or a separate incidental diagnosis. It is vital to differentiate incidental thrombotic thrombocytopenia purpura or atypical hemolytic uremic syndrome in cancer patients presenting with a TMA, as they have different treatment strategies, and prompt initiation of treatment impacts outcome. In the oncology patient, widespread microvascular metastases or extensive bone marrow involvement can cause MAHA and thrombocytopenia. A disseminated intravascular coagulation (DIC) picture may be precipitated by sepsis or driven by the cancer itself. Cancer therapies may cause a TMA, either dose-dependent toxicity, or an idiosyncratic immune-mediated reaction due to drug-dependent antibodies. Many causes of TMA seen in the oncology patient do not respond to plasma exchange and, where feasible, treatment of the underlying malignancy is important in controlling both cancer-TMA or DIC driven disease. Drug-induced TMA should be considered and any putative causal agent stopped. We will discuss the differential diagnosis and treatment of MAHA in patients with cancer using clinical cases to highlight management principles.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Thomas MR, Scully M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood. 2021. PMID: 33512445. doi:10.1182/blood.2019003810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。